Posted by Michael Wonder on 10 Apr 2019
#Orkambinow?
9 April 2019 - After a long standoff over CF treatment Orkambi, a deal looks imminent.
The long-running row over access to Vertex’s cystic fibrosis drug Orkambi has been one of the worse episodes for access to new medicines in the UK, and has reflected badly on the pharma company, budget holder NHS England and cost effectiveness watchdog NICE.
The row boiled over into accusations being traded publicly – Vertex calling the health service budget holder’s stance ‘outrageous’ last summer and NHS England’s head of specialised medicines commissioning John Stewart in January calling the pharma company an ‘extreme outlier in terms of both its pricing and behaviour”.
